Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.
about
Challenges of drug-resistant malariaMalarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, NigeriaAntimalarial drug resistanceA mechanism for the synergistic antimalarial action of atovaquone and proguanilAlternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparumDrug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drugEndochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosisAssessment of the pharmacodynamic properties of antimalarial drugs in vivo4(1H)-pyridone and 4(1H)-quinolone derivatives as antimalarials with erythrocytic, exoerythrocytic, and transmission blocking activitiesCan mutation and selection explain virulence in human P. falciparum infections?Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance markerTetracyclines in malariaDrug resistance genomics of the antimalarial drug artemisininSevere atovaquone-resistant Plasmodium falciparum malaria in a Canadian traveller returned from the Indian subcontinentThe influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic reviewP. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-actionMitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen familiesTargeting purine and pyrimidine metabolism in human apicomplexan parasitesTransformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanilIn vitro adaptation of Plasmodium falciparum reveal variations in cultivability.Independent origins of loss-of-function mutations conferring oxamniquine resistance in a Brazilian schistosome population.Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group.Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b geneEmergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reportsAntiparasitic agent atovaquoneAssessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitroMitochondrial electron transport inhibition and viability of intraerythrocytic Plasmodium falciparum.The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment.Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system.Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.Novel Mutation in Cytochrome B of Plasmodium falciparum in One of Two Atovaquone-Proguanil Treatment Failures in Travelers Returning From Same Site in NigeriaAntimalarial pharmacology and therapeutics of atovaquoneSubtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparumMolecular surveillance of mutations in the cytochrome b gene of Plasmodium falciparum in Gabon and Ethiopia.Antimalarial drug resistance and combination chemotherapy.History, dynamics, and public health importance of malaria parasite resistance.Within-Host Selection of Drug Resistance in a Mouse Model of Repeated Incomplete Malaria Treatment: Comparison between Atovaquone and Pyrimethamine.First case of emergence of atovaquone resistance in Plasmodium falciparum during second-line atovaquone-proguanil treatment in South America.
P2860
Q21032482-98F01CB5-A537-45E1-A59B-FD770248421BQ21245928-17F3A0C1-6DC6-445F-BA8F-800CAFC4562CQ22061790-2C077C2F-DFA8-4216-833F-09B07E7CFEE0Q24550657-10DC8E26-903C-4C0A-BE98-F18E1F74A391Q24550660-DC92E667-B947-4B47-88A9-DFFEEE038237Q24613311-89852FD9-BC12-49AB-A70A-B8FC9FE9E04DQ24630917-C06A68ED-F4B3-4010-8C1C-F103A7B35FF6Q24670346-12FAD675-BC7E-4357-B352-5D502F34AA34Q24757085-226B07FE-EE22-45B6-88CF-AADD5D808DCEQ24806349-C7694780-467F-4CDF-9749-F5EC058F6643Q24806780-9337F3AC-B942-4086-ABA2-CB67FE876D3FQ26778176-38BB56A3-2D31-4411-A0D1-3B4C397CB894Q26862789-CC7C4135-68D5-4313-B0B7-E71C5A36245FQ27490213-450F6248-D951-4A2F-AF72-4CDE32FD27EFQ28079877-DC492908-207C-4FCF-B3A2-69E56CB7A06EQ28481199-5BF5DF04-CD5D-4FDE-A74A-732B237B6444Q28486079-7F4DCA7B-D383-4573-A934-5E9109B6ABB0Q28629739-ED587B88-9D2D-4A3D-8E4A-D715691F0F0FQ29619882-E7DA2FCA-97F9-4F4F-BD6E-538B4BC9C003Q30277705-1D3898C9-BA71-4246-9847-23F8DE4D0D68Q30772877-2520AF9F-4DDF-4320-9E25-F5C3AFB42EFDQ33599811-BCD8C95C-8D2A-4905-8CA2-E4DEDDEF1F91Q33693150-7820D072-9A0E-45B5-BC54-FEE71CF15C62Q33898569-7C6045D0-CE8C-4672-8D56-277F4CC27879Q34058304-53606295-9930-4EE5-B228-EFB8A416F81AQ34107885-8F1B074B-7B48-484B-92BC-955AB36F04D4Q34111879-BFAB817F-51AC-4132-B2AC-B85BBC9A7E73Q34309434-78DE6834-8526-45B2-95B1-2E5CC62E6FA7Q34316859-852BD0C8-1208-4EAB-8EE3-0250C25AE204Q34499482-37D485BB-1550-442F-8100-B3F030A9F9BBQ34525226-5EA06FEB-C2E5-4BE0-833C-87E1B37F7309Q34707761-357CECE7-6C30-4221-B684-2325B94CCD19Q34802106-C86ACCCF-BEE9-4654-925B-6F9551935EB0Q35131253-CB34C822-ADFB-4BC4-901A-6FDE3DD73A77Q35168943-4C764B16-DF5A-4335-9CC2-7A8023371D89Q35191258-C743DFAB-7FD9-4762-B605-484E1DBD4FC1Q35212414-378C9885-21F6-4FF9-A613-8F6905BC4633Q35545447-5A2EBB27-BA92-4EC6-BB28-1F9142147E49Q35822252-B58CCE6C-7D0E-4482-A61D-8EE375F07BFBQ35840856-4D655102-D2F6-4C2C-BB8D-3CB00D792F1A
P2860
Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Clinical studies of atovaquone ...... mplicated malaria in Thailand.
@en
Clinical studies of atovaquone ...... mplicated malaria in Thailand.
@nl
type
label
Clinical studies of atovaquone ...... mplicated malaria in Thailand.
@en
Clinical studies of atovaquone ...... mplicated malaria in Thailand.
@nl
prefLabel
Clinical studies of atovaquone ...... mplicated malaria in Thailand.
@en
Clinical studies of atovaquone ...... mplicated malaria in Thailand.
@nl
P2093
P921
P1476
Clinical studies of atovaquone ...... mplicated malaria in Thailand.
@en
P2093
Canfield CJ
Hutchinson DB
Webster HK
P407
P577
1996-01-01T00:00:00Z